


Profile

Santen Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing and marketing of ophthalmic and anti-rheumatic pharmaceuticals to protect and improve people's eyesight and health. We have created innovative pharmaceuticals for all types of ophthalmic disorders and provide information tailored to clinical needs. As a result, we lead Japan's market for prescription ophthalmics, which represent nearly 80 percent of our net sales. With marketing and development bases in Japan, the United States and Europe, backed by first-rate R&D capabilities, we aim to increase our corporate value as a world-class company that delivers unique products to people worldwide.

Deeply aware of the sanctity of human life, we apply our unique capabilities and technologies in our areas of expertise to contribute to the health and quality of life of patients and their loved ones, and society as a whole.

SALES BY BUSINESS

Year ended March 31, 2003



Business Area	Description of Business and Major Products	Approximate Market Share/Market Position
Prescription Pharmaceuticals		
Ophthalmic Pharmaceuticals	<ul style="list-style-type: none"> In Japan, Santen's staff of some 400 medical representatives (MRs), the largest in the industry, and a product lineup covering a broad array of ophthalmic disorders have secured its market-leading position. Main products include the anti-infective ophthalmic <i>Cravit</i>; the corneal disorder treatment <i>Hyalein</i>; the glaucoma treatment <i>Detantol</i>; and the anti-allergy ophthalmic <i>Livostin</i>. Overseas, Santen markets levofloxacin ophthalmic solution (brand names: <i>Quixin</i>, <i>Oftaquix</i> and <i>Cravit</i>) and other products through a sales network that covers the United States, Europe and Asia. 	40%/Number One ¹
Anti-rheumatic Pharmaceuticals	<ul style="list-style-type: none"> We offer <i>Rimatil</i> and <i>Azulfidine EN</i>, physicians' disease modifying anti-rheumatic drugs (DMARDs) of choice for treating rheumatoid arthritis, in Japan. 	30%/Number One ¹
Over-the-counter (OTC) Pharmaceuticals	<ul style="list-style-type: none"> Our OTC pharmaceuticals business consists of market-leading eye drop brands in Japan such as <i>Sante FX Neo</i>, the <i>Sante 40</i> series and the <i>Sante de u</i> series. 	20%/Number Two ²
Medical Devices	<ul style="list-style-type: none"> Santen handles medical devices used in cataract surgery, including intraocular lenses, phacoemulsification machines and instruments, in Japan. 	—

Notes: 1. Market share and market position in Japan for the year ended March 31, 2003. Source: Santen Pharmaceutical Co., Ltd.

2. Market share and market position in the Japanese OTC eye drop market for the year ended March 31, 2003. Source: Santen Pharmaceutical Co., Ltd.

Contents

Financial Highlights.....	1	Production.....	24
To Our Shareholders.....	2	Personnel Development	26
An Interview with CEO Takakazu Morita on the 2003-2005 Medium-term Management Plan.....	3	Corporate Citizenship	27
Corporate Governance	8	Financial Review	28
Board of Directors, Corporate Auditors and Corporate Officers	9	Six-year Summary of Selected Financial Data	35
Research.....	10	Consolidated Financial Statements	36
Development.....	13	Independent Auditors' Report	51
Marketing.....	16	Major Subsidiaries and Facilities.....	52
		Corporate Information.....	53